Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
£ 1.07
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures...
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is undervalued on EV/EBITDA.
Data is available to registered users only
Buy
Sell